Erik previously built and led data science and engineering at Prometheus Biosciences through IPO to $10.8B acquisition by Merck, evaluated investments at Takeda Ventures, and trained as a physician-data scientist including a postdoctoral fellowship at MIT and Harvard. His publications and patents range from leveraging genetics to predict treatment response in autoimmune disease to applying deep learning methods on multimodal clinical and physiological data.